SGLT2 Inhibitors and GLP-1 Receptor Agonists in PAD: A State-of-the-Art Review
Journal of Clinical Medicine · 06.08.2025 · 14 (15) · 5549
DOI: 10.3390/jcm14155549 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 06.08.2025. Verfasst von Alfredo Caturano und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Sciences and Promotion of the Quality of Life, San Raffaele Roma Open University, 00166 Rome, Italy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Sodium–glucose co-transporter-2 inhibitors (SGLT2is) and GLP-1 receptor agonists (GLP-1 RAs) are now established as cornerstone therapies for patients with type 2 diabetes mellitus (T2DM), given their cardiovascular and renal protective properties. However, their use in patients with peripheral artery disease (PAD) remains controversial due to concerns raised in early trials about potential increases in lower limb complications, particularly amputations. This narrative review examines current evidence on the association between SGLT2is and GLP-1 RAs in PAD-related outcomes, including limb events, amputation risk, and cardiovascular and renal endpoints. Drawing from randomized controlled trials, real-world cohort studies, and systematic reviews, we provide an integrated perspective on the safety and utility of SGLT2is and GLP-1 RAs in individuals with PAD, highlight patient selection considerations, and identify areas for future investigation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Human Sciences and Promotion of the Quality of Life, San Raffaele Roma Open University, 00166 Rome, Italy.
- Institute of "Clinica Medica", Department of Medicine and Aging Science, "G. d'Annunzio" University of Chieti-Pescara, 66100 Chieti, Italy.
- Angiology Unit, Internal Medicine Department, Città S. Angelo Hospital, Città S. Angelo, 65013 Pescara, Italy.
- Department of Life, Health & Environmental Sciences and Internal Medicine, ASL Avezzano-Sulmona-L'Aquila, San Salvatore Hospital, University of L'Aquila, 67100 L'Aquila, Italy.
- Internal Medicine, IRCCS Azienda Ospedaliero-Universitaria Policlinico di Sant'Orsola, 40138 Bologna, Italy.
- Internal Medicine Unit, Val Vibrata Hospital-Sant'Omero (TE), Department of Life, Health and Environmental Sciences, University of L'Aquila, 67100 L'Aquila, Italy.
ORCID-Profile: Alfredo Caturano, Damiano D'Ardes, Davide Grassi, Carla Serra, Maria Teresa Guagnano, Fabio Piscaglia, Andrea Boccatonda
Zitieren
APA
Caturano, A., D'Ardes, D., Simeone, P. G., Lessiani, G., Gregorio, N. D., Andreetto, L., Grassi, D., Serra, C., Santilli, F., Guagnano, M. T., Piscaglia, F., Ferri, C., Cipollone, F., & Boccatonda, A. (2025). SGLT2 Inhibitors and GLP-1 Receptor Agonists in PAD: A State-of-the-Art Review. Journal of Clinical Medicine, 14(15), 5549. https://doi.org/10.3390/jcm14155549
Vancouver
Caturano A, D'Ardes D, Simeone PG, Lessiani G, Gregorio ND, Andreetto L, et al. SGLT2 Inhibitors and GLP-1 Receptor Agonists in PAD: A State-of-the-Art Review. Journal of Clinical Medicine. 2025;14(15):5549. doi:10.3390/jcm14155549
BibTeX
@article{Caturano2025,
author = {Caturano, Alfredo and D'Ardes, Damiano and Simeone, Paola Giustina and Lessiani, Gianfranco and Gregorio, Nicoletta Di and Andreetto, Lorenzo and Grassi, Davide and Serra, Carla and Santilli, Francesca and Guagnano, Maria Teresa and Piscaglia, Fabio and Ferri, Claudio and Cipollone, Francesco and Boccatonda, Andrea},
title = {SGLT2 Inhibitors and GLP-1 Receptor Agonists in PAD: A State-of-the-Art Review},
journal = {Journal of Clinical Medicine},
year = {2025},
volume = {14},
number = {15},
pages = {5549},
doi = {10.3390/jcm14155549}
}
EUVIMED